Michael Sigouros
Overview
Explore the profile of Michael Sigouros including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1033
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nguyen D, Hooper W, Liu W, Chu T, Geiger H, Shelton J, et al.
Nature
. 2024 Oct;
635(8037):219-228.
PMID: 39385020
Advanced urothelial cancer is a frequently lethal disease characterized by marked genetic heterogeneity. In this study, we investigated the evolution of genomic signatures caused by endogenous and external mutagenic processes...
12.
Hissong E, Bhinder B, Kim J, Ohara K, Ravichandran H, Al Assaad M, et al.
Res Sq
. 2024 Aug;
PMID: 39108491
Colorectal carcinoma (CRC) is a heterogeneous group of tumors with varying therapeutic response and prognosis, and evidence suggests the tumor immune microenvironment (TIME) plays a pivotal role. Using advanced molecular...
13.
Al Assaad M, Michaud O, Semaan A, Sigouros M, Tranquille M, Phan A, et al.
Mod Pathol
. 2024 Feb;
37(4):100452.
PMID: 38369186
The molecular characterization of male breast cancer (MaBC) has received limited attention in research, mostly because of its low incidence rate, accounting for only 0.5% to 1% of all reported...
14.
Al Assaad M, Shin N, Sigouros M, Manohar J, Antysheva Z, Kotlov N, et al.
Front Oncol
. 2024 Feb;
13:1274163.
PMID: 38318324
Cancer of unknown primary (CUP) represents a significant diagnostic and therapeutic challenge, being the third to fourth leading cause of cancer death, despite advances in diagnostic tools. This article presents...
15.
Franceschini G, Quaini O, Mizuno K, Orlando F, Ciani Y, Ku S, et al.
Cancer Discov
. 2024 Jan;
14(3):424-445.
PMID: 38197680
Significance: Neuroendocrine prostate cancer is an aggressive subtype of treatment-resistant prostate cancer. Early detection is important, but the diagnosis currently relies on metastatic biopsy. We describe the development and validation...
16.
Hissong E, Al Assaad M, Bal M, Reed K, Fornelli A, Levine M, et al.
Am J Surg Pathol
. 2023 Dec;
48(2):183-193.
PMID: 38047392
Several reports describing a rare primary liver tumor with histologic features reminiscent of follicular thyroid neoplasms have been published under a variety of descriptive terms including thyroid-like, solid tubulocystic, and...
17.
Author Correction: Evolution of structural rearrangements in prostate cancer intracranial metastases
Khani F, Hooper W, Wang X, Chu T, Shah M, Winterkorn L, et al.
NPJ Precis Oncol
. 2023 Nov;
7(1):113.
PMID: 37919447
No abstract available.
18.
Khani F, Hooper W, Wang X, Chu T, Shah M, Winterkorn L, et al.
NPJ Precis Oncol
. 2023 Sep;
7(1):91.
PMID: 37704749
Intracranial metastases in prostate cancer are uncommon but clinically aggressive. A detailed molecular characterization of prostate cancer intracranial metastases would improve our understanding of their pathogenesis and the search for...
19.
Sumiyoshi T, Wang X, Warner E, Sboner A, Annala M, Sigouros M, et al.
J Natl Cancer Inst
. 2023 Sep;
116(1):115-126.
PMID: 37676819
Background: The phase 3 CALGB 90203 (Alliance) trial evaluated neoadjuvant chemohormonal therapy for high-risk localized prostate cancer before radical prostatectomy. We dissected the molecular features of post-treated tumors with long-term...
20.
Setton J, Hadi K, Choo Z, Kuchin K, Tian H, Da Cruz Paula A, et al.
Nature
. 2023 Aug;
621(7977):129-137.
PMID: 37587346
Homologous recombination (HR) deficiency is associated with DNA rearrangements and cytogenetic aberrations. Paradoxically, the types of DNA rearrangements that are specifically associated with HR-deficient cancers only minimally affect chromosomal structure....